Larimar Therapeutics/$LRMR

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Larimar Therapeutics

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Ticker

$LRMR
Sector
Primary listing

Employees

65

LRMR Metrics

BasicAdvanced
$318M
-
-$1.56
0.94
-

What the Analysts think about LRMR

Analyst ratings (Buy, Hold, Sell) for Larimar Therapeutics stock.

Bulls say / Bears say

Deerfield Management, the company’s largest shareholder, showed interest in acquiring shares in the recent equity raise, demonstrating strong insider confidence in the advancement of nomlabofusp.
All 12 analysts covering Larimar have Buy ratings and a median price target of $18, suggesting considerable upside from current price levels.
Larimar intends to use the net proceeds to fund development of its lead candidate nomlabofusp and other pipeline programs, supporting continued progress in its rare disease portfolio.
Shares of Larimar Therapeutics dropped 9.6% premarket to $3.19 after the company priced 18.75 million shares at $3.20, raising $60 million in gross proceeds and highlighting significant investor worries over dilution.
The equity offering was carried out at a 9.3% discount to the previous closing price, indicating weak demand and downward pricing pressure for Larimar’s stock.
During after-hours trading, shares declined 10.8% to $3.15 as Larimar announced an offering of common stock and pre-funded warrants, pointing to persistent market skepticism.
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.

LRMR Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

LRMR Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $LRMR

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs